Identification of New Antibodies Targeting Malignant Plasma Cells for Immunotherapy by Next-Generation Sequencing-Assisted Phage Display

Autor: Steffen Krohn, Ammelie Svea Boje, Carina Lynn Gehlert, Sebastian Lutz, Nikos Darzentas, Henrik Knecht, Dietrich Herrmann, Monika Brüggemann, Axel J. Scheidig, Katja Weisel, Martin Gramatzki, Matthias Peipp, Katja Klausz

Publikováno v: Frontiers in Immunology, Vol 13 (2022)

To identify new antibodies for the treatment of plasma cell disorders including multiple myeloma (MM), a single-chain Fragment variable (scFv) antibody library was generated by immunizing mice with patient-derived malignant plasma cells. To enrich an

Externí odkaz: https://doaj.org/article/67012a1ee1a04392926447c7d0107282

Quality control and quantification in IG/TR next-generation sequencing marker identification: protocols and bioinformatic functionalities by EuroClonality-NGS

Autor: Jos Rijntjes, K. Stamatopoulos, C. Pott, Ramón García-Sanz, Karla Plevová, Giovanni Cazzaniga, Elizabeth Macintyre, Nikos Darzentas, Blanca Scheijen, John Moppett, F. Appelt, Jack Bartram, Eva Froňková, Michael Svatoň, Frederic Davi, Michaela Kotrova, Jan Trka, Simona Songia, Kamila Stránská, Andrea Grioni, Henrik Knecht, Monika Brüggemann, David Gonzalez, Dietrich Herrmann, Michael Hummel, Karol Pál, Anthonie Willem Langerak, Tomáš Reigl, Adam Krejci, van Dongen Jjm, Groenen Pjta, J. Hancock, Peter Stewart, Bystry

Publikováno v: Leukemia
Leukemia, 33, 9, pp. 2254-2265
Leukemia, 33(9), 2254-2265. Nature Publishing Group
Digital.CSIC. Repositorio Institucional del CSIC
instname
Leukemia, 33, 2254-2265
Leukemia, 33(9), 2254-2265. NATURE PUBLISHING GROUP
EuroClonality-NGS Working Group 2019, ' Quality control and quantification in IG/TR next-generation sequencing marker identification: protocols and bioinformatic functionalities by EuroClonality-NGS ', Leukemia . https://doi.org/10.1038/s41375-019-0499-4

Assessment of clonality, marker identification and measurement of minimal residual disease (MRD) of immunoglobulin (IG) and T cell receptor (TR) gene rearrangements in lymphoid neoplasms using next-generation sequencing (NGS) is currently under inten

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de78cda79a5e6031838658ea5f867c70
https://hdl.handle.net/1887/121552

The IG/TR Next Generation Marker Screening Developed within Euroclonality-NGS Consortium Is Successful in 94% of Acute Lymphoblastic Leukemia Samples

Autor: Martin Schwarz, Nicola Goekbuget, Karin Olsen, Dietrich Herrmann, Heiko Trautmann, Henrik Knecht, Michaela Kotrova, Monika Brüggemann, Nikos Darzentas, Christiane Pott

Publikováno v: Blood. 132:2830-2830

Introduction The current gold standard molecular method for minimal residual disease (MRD) assessment is RQ-PCR for detection of leukemia-associated immunoglobulin (IG) and T cell receptor (TR) rearrangements, which must be identified beforehand in t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0677a7d6d9820f6c51d68c8029483b62
https://doi.org/10.1182/blood-2018-99-112828

High-throughput, Amplicon-Based sequencing of the CREBBP gene as a tool to develop a universal platform-independent assay

Autor: Dietrich Herrmann, Monika Brüggemann, Michael Kneba, Sven Kuenzel, Henrik Knecht, Marc W. Fuellgrabe, Christiane Pott

Publikováno v: PLoS One
PLoS ONE
PLoS ONE, Vol 10, Iss 6, p e0129195 (2015)

High-throughput sequencing technologies are widely used to analyse genomic variants or rare mutational events in different fields of genomic research, with a fast development of new or adapted platforms and technologies, enabling amplicon-based analy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::943909b7b7ae134957cd617a2d405c08
https://hdl.handle.net/11858/00-001M-0000-0027-BA30-B11858/00-001M-0000-0027-BA32-7

Erratum: GvL effects in T-prolymphocytic leukemia: evidence from MRD kinetics and TCR repertoire analyses

Autor: Thomas Luft, Nikos Darzentas, Monika Brüggemann, Adam Krejci, Michael Kneba, Vojtech Bystry, Peter Dreger, Tomáš Reigl, Sascha Dietrich, Henrik Knecht, Michael Rieger, Dietrich Herrmann, Max Schlitt, Leopold Sellner, Anthony D. Ho

Publikováno v: Bone Marrow Transplantation. 52:656-656

Allogeneic stem cell transplantation (alloSCT) is used for treating patients with T-prolymphocytic leukemia (T-PLL). However, direct evidence of GvL activity in T-PLL is lacking. We correlated minimal residual disease (MRD) kinetics with immune inter

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::454e9fbd715acc5e7a8c03ad62ef433a
https://doi.org/10.1038/bmt.2017.12